Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells

Erming Tian, PhD MBA, Jeffery R. Sawyer, Ricky D. Edmondson, Maurizio Zangari, MD, Christopher P. Wardell, PhD MSc, BSc, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD

Blood (2019) 134 (Supplement_1): 4390.

https://doi.org/10.1182/blood-2019-131850

Published: 2019

Journal Articles

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

Jeffery R. Sawyer, Erming Tian, PhD MBA, Brian A Walker, PhD, Christopher P. Wardell, PhD MSc, BSc, Joshua Epstein, DSc, Janet L Lukacs, Gael M. Sammartino, Clyde Bailey, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Faith E. Davies, MD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2018-99-115090

Published: 2018

Journal Articles

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

Aneta Mikulasova, PhD, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Michael Bauer, PhD, Konstantimos Mavrommatis, PhD, Christopher P. Wardell, PhD, Matthew Trotter, PhD, Shayu Deshpande, Owen W. Stephens, Erming Tian, PhD MBA, Graham Jackson, Faith E. Davies, MD, Anjan Thakurta, PhD, Nikhil Munshi, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 65.

https://doi.org/10.1182/blood.V130.Suppl_1.65.65

Published: 2017

Journal Articles

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Meera Mohan, MD, Niels Weinhold, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Leo Rasche, MD, Jeffery R. Sawyer, Erming Tian, PhD MBA, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Maurizio Zangari, MD

Blood (2017) 130 (Supplement 1): 4373.

https://doi.org/10.1182/blood.V130.Suppl_1.4373.4373

Published: 2017

Journal Articles

Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma

Jeffery R. Sawyer, Erming Tian, PhD MBA, Brian A Walker, PhD, Charles M. Swanson, Janet L Lukacs, Gael M. Sammartino, Clyde Bailey, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 3060.

https://doi.org/10.1182/blood.V130.Suppl_1.3060.3060

Published: 2017

NARROW

The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only